Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series

Journal of Ovarian Research

Stephanie Yacoub¹  Kenneth Cadesky²  Robert F. Casper³ 

[1] Present address: Department of Obstetrics and Gynecology, Saint Georges Hospital University Medical Center, Beirut, Lebanon;TRIO Fertility, and Department of Obstetrics and Gynecology, University of Toronto, 655 Bay St, Suite 1101, M5G2K4, Toronto, ON, Canada;TRIO Fertility, and Department of Obstetrics and Gynecology, University of Toronto, 655 Bay St, Suite 1101, M5G2K4, Toronto, ON, Canada;Lunenfeld-Tanenbaum Research Institute, Mount Sinai System, Toronto, ON, Canada;

关键词: Polycystic ovary syndrome;    Rotterdam criteria;    Follitropin delta;    Recombinant FSH;    OHSS;   

DOI  :  10.1186/s13048-021-00773-5

来源: Springer

【 摘 要 】

BackgroundTo explore the efficacy of follitropin delta in ovarian stimulation of patients with the Rotterdam ESHRE/ASRM 2003 phenotypes of polycystic ovarian syndrome (PCOS) using a retrospective case series with an electronic file search in a reproductive medicine clinic.Case presentationSeventy-four patients with PCOS undergoing ovarian stimulation according to the individualized dosing algorithm of follitropin delta for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)/oocyte freezing were included. Follitropin delta resulted in a high number of pre-ovulatory follicles at the end of stimulation as expected in patients with PCOS. There was a large number of oocytes retrieved with an acceptable percentage of metaphase II (MII) oocytes. There were no cases of moderate or severe OHSS across all phenotypes.ConclusionFollitropin delta, using the individualized dosing algorithm, appears to be a safe method of ovarian stimulation with a low risk of OHSS in PCOS patients without sacrificing successful stimulation outcomes.

【 授权许可】

CC BY